Active, Not Recruiting
Observational Study for Lung Cancer Patients Treated With Nivolumab - CA209-417
Updated: 19 June, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Male or female: 18 age at the time of nivolumab initiation - Pathologically confirmed diagnosis of lung cancer - Patient initiating nivolumab :therapeutic decision to initiate nivolumab must be taken by the physician prior to enrolling a patient in the study Exclusion Criteria: -Patient taking part in an interventional study for lung cancer treatment for which nivolumab is 1 of the investigational drugs Other protocol defined inclusion or exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
